Vincent Verschraegen, country manager of Mylan Belgium and Luxembourg, speaks about his onboarding in the company and what attracted him to join the organization. Verschraegen also discusses Mylan’s evolution from a pure generics player to a full solution healthcare provider and offers insights into Belgium’s complex biosimilar landscape as well as the changes which must be realized in order to fully unlock the opportunities of this growing segment.
In terms of pricing, the average biosimilar coming to market is 30 to 38 percent lower in price than the originator ... Biosimilars currently available in Belgium are already generating more than EUR 270 million savings annually
